Bay Harbor Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bay Harbor Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.21K	Buy	14 +3	+27%	+$905	﹤0.01%	460
2026 Q1	$3.64K	Buy	11 +2	+22%	+$681	﹤0.01%	405
2025 Q4	$3.58K	Buy	9 +3	+50%	+$1.33K	﹤0.01%	347
2025 Q3	$2.74K	Hold	6	–	–	﹤0.01%	311
2025 Q2	$1.96K	Buy	6 +4	+200%	+$1.11K	﹤0.01%	315
2025 Q1	$540	Buy	+2	New	+$514	﹤0.01%	412

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bay Harbor Wealth Management's ALNY Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 27% in Q2 2026, buying an estimated $905 and bringing the position to 14 shares worth $4.21K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Bay Harbor Wealth Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Bay Harbor Wealth Management held 14 shares of Alnylam Pharmaceuticals worth $4.21K as of Q2 2026.
Bay Harbor Wealth Management bought 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
Alnylam Pharmaceuticals made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #460 holding.
Bay Harbor Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.